MA50636A - Compositions et procédés pour inhiber l'activité d'arginase - Google Patents
Compositions et procédés pour inhiber l'activité d'arginaseInfo
- Publication number
- MA50636A MA50636A MA050636A MA50636A MA50636A MA 50636 A MA50636 A MA 50636A MA 050636 A MA050636 A MA 050636A MA 50636 A MA50636 A MA 50636A MA 50636 A MA50636 A MA 50636A
- Authority
- MA
- Morocco
- Prior art keywords
- arginase
- inhibiting
- compositions
- activity
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248632P | 2015-10-30 | 2015-10-30 | |
| US201662281964P | 2016-01-22 | 2016-01-22 | |
| US201662323034P | 2016-04-15 | 2016-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50636A true MA50636A (fr) | 2021-04-14 |
Family
ID=58631120
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050636A MA50636A (fr) | 2015-10-30 | 2016-10-28 | Compositions et procédés pour inhiber l'activité d'arginase |
| MA43131A MA43131B1 (fr) | 2015-10-30 | 2016-10-28 | Compositions et procédés d'inhibition de l'activité de l'arginase |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43131A MA43131B1 (fr) | 2015-10-30 | 2016-10-28 | Compositions et procédés d'inhibition de l'activité de l'arginase |
Country Status (36)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103068830B (zh) | 2010-04-22 | 2016-06-29 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| WO2017075363A1 (en) | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3538111B1 (en) | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| SMT202100573T1 (it) | 2016-12-22 | 2021-11-12 | Calithera Biosciences Inc | Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi |
| WO2018209290A1 (en) * | 2017-05-12 | 2018-11-15 | Calithera Biosciences, Inc. | Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide |
| US11655260B2 (en) | 2017-12-22 | 2023-05-23 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as arginase inhibitors |
| TWI803574B (zh) | 2018-02-17 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 精胺酸酶抑制劑及其使用方法 |
| CN111818928A (zh) | 2018-03-05 | 2020-10-23 | 艾库斯生物科学有限公司 | 精氨酸酶抑制剂 |
| EP3765006A4 (en) * | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| EP3774843B1 (en) | 2018-03-29 | 2022-05-25 | Molecure SA | Dipeptide piperidine derivatives |
| EP3810615B1 (en) | 2018-06-20 | 2026-01-28 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| ES3034676T3 (en) | 2018-11-16 | 2025-08-21 | Arcus Biosciences Inc | Inhibitors of arg1 and/or arg2 |
| CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
| US12240867B2 (en) | 2018-12-18 | 2025-03-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| CN113614095B (zh) * | 2019-02-06 | 2024-08-23 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的烷基硼酸类化合物 |
| WO2020223728A1 (en) * | 2019-05-02 | 2020-11-05 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
| CN119119095A (zh) * | 2019-07-23 | 2024-12-13 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| CN110615753A (zh) * | 2019-09-02 | 2019-12-27 | 南京新酶合医药科技有限公司 | 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法 |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| KR20220100904A (ko) | 2019-11-12 | 2022-07-18 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 ido 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| EP4087583B1 (en) * | 2020-01-07 | 2026-04-22 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US20220041630A1 (en) * | 2020-07-17 | 2022-02-10 | Incyte Corporation | Processes for the preparation of arginase inhibitors and their synthetic intermediates |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| WO2024086273A1 (en) | 2022-10-21 | 2024-04-25 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| TW202440086A (zh) | 2023-03-13 | 2024-10-16 | 美商英塞特公司 | 作為激酶抑制劑之雙環脲 |
| WO2026076207A1 (en) | 2024-10-04 | 2026-04-09 | Incyte Corporation | Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| DK0999825T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| WO1999019295A1 (en) | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| JP2004502948A (ja) | 2000-07-06 | 2004-01-29 | ファル ダイアグノスティクス | アルギニン化合物の検出のための方法及びキット |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| CA2534484A1 (en) | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| WO2007005620A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Arginase ii: a target treatment of aging heart and heart failure |
| US20100189544A1 (en) | 2007-07-12 | 2010-07-29 | Sanyo Denki Co., Ltd. | Counter-rotating axial-flow fan |
| JP5421272B2 (ja) * | 2007-10-12 | 2014-02-19 | リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド | 眼病治療のための組成物及び方法 |
| JP2011519868A (ja) * | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | 癌を処置するための化学療法剤の連続投与 |
| SI2389352T1 (sl) * | 2009-01-26 | 2019-08-30 | The Trustees Of The University Of Pennsylvania, Center For Technology Transfer | Inhibitorji arginaze in postopki uporabe |
| CN103068830B (zh) | 2010-04-22 | 2016-06-29 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
| DK2632927T3 (en) * | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| CA2824599C (en) | 2010-12-31 | 2020-03-10 | Astrazeneca Uk Limited | Arginase inhibitors and methods of use thereof |
| US9266908B2 (en) | 2011-10-19 | 2016-02-23 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| RU2014120166A (ru) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина |
| CA2870526C (en) * | 2012-04-18 | 2020-05-05 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| SG11201503459SA (en) * | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| CN105879030A (zh) * | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| CN107405404A (zh) * | 2015-03-20 | 2017-11-28 | 塞米·欧尤·奥皮约 | 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途 |
| KR20180021117A (ko) | 2015-06-23 | 2018-02-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성 억제를 위한 조성물 및 방법 |
| WO2017075363A1 (en) | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
-
2016
- 2016-10-28 WO PCT/US2016/059342 patent/WO2017075363A1/en not_active Ceased
- 2016-10-28 CR CR20210390A patent/CR20210390A/es unknown
- 2016-10-28 CN CN202110099502.4A patent/CN113150016A/zh active Pending
- 2016-10-28 CN CN202110097870.5A patent/CN113150015A/zh active Pending
- 2016-10-28 AU AU2016343656A patent/AU2016343656B2/en not_active Ceased
- 2016-10-28 ES ES16860883T patent/ES2808988T3/es active Active
- 2016-10-28 CA CA3003271A patent/CA3003271A1/en active Pending
- 2016-10-28 EA EA201891057A patent/EA038276B1/ru unknown
- 2016-10-28 JP JP2018522126A patent/JP6833844B2/ja active Active
- 2016-10-28 RS RS20200836A patent/RS60695B1/sr unknown
- 2016-10-28 MY MYPI2018701596A patent/MY201783A/en unknown
- 2016-10-28 PH PH1/2018/500899A patent/PH12018500899B1/en unknown
- 2016-10-28 MA MA050636A patent/MA50636A/fr unknown
- 2016-10-28 TW TW105135189A patent/TWI710565B/zh not_active IP Right Cessation
- 2016-10-28 CR CR20210389A patent/CR20210389A/es unknown
- 2016-10-28 HU HUE16860883A patent/HUE054972T2/hu unknown
- 2016-10-28 SG SG10201911402YA patent/SG10201911402YA/en unknown
- 2016-10-28 DK DK22150809.6T patent/DK4011887T3/da active
- 2016-10-28 MX MX2018005294A patent/MX2018005294A/es unknown
- 2016-10-28 SG SG11201802961PA patent/SG11201802961PA/en unknown
- 2016-10-28 LT LTEP16860883.4T patent/LT3368541T/lt unknown
- 2016-10-28 UA UAA201805902A patent/UA125289C2/uk unknown
- 2016-10-28 NZ NZ742742A patent/NZ742742A/en not_active IP Right Cessation
- 2016-10-28 EP EP16860883.4A patent/EP3368541B1/en active Active
- 2016-10-28 PH PH1/2022/551082A patent/PH12022551082A1/en unknown
- 2016-10-28 DK DK16860883.4T patent/DK3368541T3/da active
- 2016-10-28 ES ES22150809T patent/ES2991555T3/es active Active
- 2016-10-28 HR HRP20201046TT patent/HRP20201046T1/hr unknown
- 2016-10-28 SI SI201630892T patent/SI3368541T1/sl unknown
- 2016-10-28 US US15/337,041 patent/US10065974B2/en active Active
- 2016-10-28 KR KR1020227028040A patent/KR20220118559A/ko active Pending
- 2016-10-28 CN CN202110099500.5A patent/CN113201002A/zh active Pending
- 2016-10-28 SM SM20200469T patent/SMT202000469T1/it unknown
- 2016-10-28 SG SG10202003966RA patent/SG10202003966RA/en unknown
- 2016-10-28 EP EP22150809.6A patent/EP4011887B1/en active Active
- 2016-10-28 PT PT168608834T patent/PT3368541T/pt unknown
- 2016-10-28 ES ES20165627T patent/ES2910928T3/es active Active
- 2016-10-28 BR BR112018008746-7A patent/BR112018008746B1/pt not_active IP Right Cessation
- 2016-10-28 TW TW110129153A patent/TWI775556B/zh not_active IP Right Cessation
- 2016-10-28 MD MDE20180870T patent/MD3368541T2/ro unknown
- 2016-10-28 KR KR1020187015208A patent/KR102434308B1/ko active Active
- 2016-10-28 PL PL16860883T patent/PL3368541T3/pl unknown
- 2016-10-28 TW TW109135297A patent/TWI734630B/zh not_active IP Right Cessation
- 2016-10-28 CN CN201680063897.XA patent/CN108271371B/zh active Active
- 2016-10-28 CR CR20180282A patent/CR20180282A/es unknown
- 2016-10-28 BR BR122020022280-8A patent/BR122020022280B1/pt active IP Right Grant
- 2016-10-28 SG SG10201911406TA patent/SG10201911406TA/en unknown
- 2016-10-28 BR BR122020022275-1A patent/BR122020022275B1/pt active IP Right Grant
- 2016-10-28 MA MA43131A patent/MA43131B1/fr unknown
- 2016-10-28 EP EP20165627.9A patent/EP3693375B1/en active Active
-
2018
- 2018-04-16 IL IL258731A patent/IL258731B/en active IP Right Grant
- 2018-04-27 CL CL2018001134A patent/CL2018001134A1/es unknown
- 2018-05-02 CO CONC2018/0004750A patent/CO2018004750A2/es unknown
- 2018-05-28 EC ECIEPI201840250A patent/ECSP18040250A/es unknown
- 2018-05-29 ZA ZA2018/03556A patent/ZA201803556B/en unknown
- 2018-08-10 US US16/101,275 patent/US10851118B2/en not_active Expired - Fee Related
-
2019
- 2019-03-28 CL CL2019000820A patent/CL2019000820A1/es unknown
- 2019-03-28 CL CL2019000819A patent/CL2019000819A1/es unknown
- 2019-03-28 CL CL2019000821A patent/CL2019000821A1/es unknown
- 2019-10-28 ZA ZA2019/07091A patent/ZA201907091B/en unknown
- 2019-10-28 ZA ZA2019/07093A patent/ZA201907093B/en unknown
- 2019-10-28 ZA ZA2019/07092A patent/ZA201907092B/en unknown
-
2020
- 2020-03-23 US US16/827,503 patent/US10844080B2/en active Active
- 2020-08-21 CY CY20201100780T patent/CY1123557T1/el unknown
- 2020-11-12 US US17/096,500 patent/US20210061822A1/en not_active Abandoned
- 2020-12-10 AU AU2020286278A patent/AU2020286278B2/en not_active Ceased
-
2021
- 2021-02-02 JP JP2021014795A patent/JP7032583B2/ja not_active Expired - Fee Related
- 2021-03-15 IL IL281503A patent/IL281503B/en unknown
- 2021-11-18 IL IL288225A patent/IL288225A/en unknown
-
2022
- 2022-02-22 JP JP2022025334A patent/JP2022071010A/ja not_active Withdrawn
- 2022-05-31 AU AU2022203703A patent/AU2022203703A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| MA42269A (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| IL267532B (en) | Preparations and methods for inhibiting arginase activity | |
| MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3353309A4 (en) | COMPOSITIONS AND METHOD FOR GENERIC EDITING | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3325017A4 (en) | OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR | |
| EP3386484A4 (en) | COMPOSITIONS AND METHODS OF DELIVERING THERAPEUTIC ACTIVITIES | |
| EP3635100A4 (en) | COMPOSITIONS AND METHOD OF EXPRESSION OF OTOFERLIN | |
| EP3273944A4 (en) | COMPOSITIONS AND METHODS OF DISTRIBUTING BIOMACROMOLOLE-ACIDS | |
| EP3386550A4 (en) | METHOD AND COMPOSITIONS FOR THE PREPARATION AND USE OF LEADNUCLEIC ACIDS | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA41253A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| EP3359693A4 (en) | METHOD AND COMPOSITIONS FOR ENRICHING AMPLIFICATION PRODUCTS | |
| MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
| EP3267995A4 (en) | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF FIBROSIS | |
| EP3289064A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING ALLERGENS | |
| EP3349743A4 (en) | METHOD AND COMPOSITIONS FOR INHIBITING DCN1-UBC12 INTERACTION | |
| EP3302558A4 (en) | ANTI-TUMOR MEDIUM AND METHOD OF USE | |
| EP3488018A4 (en) | METHOD AND COMPOSITIONS FOR PROTEIN IDENTIFICATION | |
| EP3389673A4 (en) | METHOD AND COMPOSITIONS FOR RELEASING POLYNUCLEOTIDES | |
| EP3373950A4 (en) | METHOD AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICATIONS | |
| EP3458448A4 (en) | METHOD OF USE OF FASN INHIBITORS | |
| EP3261631A4 (en) | INHIBITION OF OLIG2 ACTIVITY | |
| MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants |